Lipocine, Pharmalink Commercialize Tlando

This is a Tlando news story, published by Yahoo Finance, that relates primarily to the Gulf Cooperation Council news.

Tlando news

For more Tlando news, you can click here:

more Tlando news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Tlando drug product

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Tlando news, Pharmalink news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Lipocine

TipRanks

•

Lipocine signs supply and distribution agreement with Pharmalink for Tlando

Summary

Nutrition label

77% Informative

Lipocine announced an exclusive supply and distribution agreement with Pharmalink to commercialize Tlando , its oral testosterone replacement therapy, in the Gulf Cooperation Council countries.

Pharmalinks will have the exclusive rights to Tlando throughout the GCC region and will be responsible for promotion, distribution and sale of the product.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful